Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Marek Regina

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/15/2019

3. Issuer Name and Ticker or Trading Symbol

Aerpio Pharmaceuticals, Inc. [ARPO]

(Last) (First) (Middle)

C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Vice President of Finance /

(Street)

CINCINNATI, OH 45242

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11625	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	8/9/2028	Common Stock	80000	$3.4852	D
Stock Option (Right to Buy)	⁽²⁾	2/15/2029	Common Stock	30000	$3.27	D
Stock Option (Right to Buy)	⁽³⁾	5/14/2029	Common Stock	153300	$1.04	D

Explanation of Responses:
(1)	Options exercisable as to 1/4th on August 1, 2019 and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date.
(2)	Options exercisable as to 1/4th on February 15, 2020 and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date.
(3)	50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021.

Remarks:
Exhibit 24: Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Marek Regina C/O AERPIO PHARMACEUTICALS, INC. 9987 CARVER ROAD, SUITE 420 CINCINNATI, OH 45242			Vice President of Finance